Tobramycin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Tobramycin: From Bacterial Infections to Exposure Keratitis
One-Sentence Summary
Tobramycin is an aminoglycoside antibiotic classically used to treat serious bacterial infections, particularly those caused by Pseudomonas aeruginosa (e.g., cystic fibrosis pulmonary infections, and topical ophthalmic/otic infections). The TxGNN model predicts it may also be relevant for Exposure Keratitis, but this direction is currently supported only by 2 clinical trials (neither directly testing tobramycin for this condition) and 7 publications, most of which are case reports or in vitro toxicity studies rather than direct efficacy evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the current EU regulatory dataset (drug not marketed); tobramycin is generally indicated for serious bacterial infections, particularly Pseudomonas aeruginosa infections |
| Predicted New Indication | Exposure Keratitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on general pharmacological knowledge, tobramycin is an aminoglycoside antibiotic that binds the bacterial 30S ribosomal subunit to inhibit protein synthesis, producing bactericidal activity against Gram-negative organisms — most notably Pseudomonas aeruginosa — as well as several Gram-positive species. Its efficacy against these pathogens is well established across respiratory (inhaled formulations for cystic fibrosis), ophthalmic (topical drops for bacterial conjunctivitis/keratitis), and otic (external otitis) uses.
Exposure keratitis is a corneal surface disorder caused by inadequate eyelid closure (e.g., in sedated, comatose, or neurologically impaired patients), which predisposes the exposed cornea to desiccation and secondary bacterial infection by common ocular pathogens such as Pseudomonas and Staphylococcus species — organisms tobramycin is well suited to treat. This creates a plausible pharmacological rationale for tobramycin as prophylaxis or treatment of secondary bacterial infection in exposure keratitis.
However, the underlying rationale in this Evidence Pack explicitly notes that tobramycin’s role would be adjunctive antibacterial protection against secondary infection, not treatment of the exposure keratitis disease process itself (which is fundamentally a mechanical/eyelid-closure problem). This distinction is important: the prediction reflects a plausible but narrow, supportive use case rather than a disease-modifying new indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06200727 | N/A | Unknown | 170 | Evaluates platelet-rich fibrin (PRF) membrane across four ophthalmic conditions (macular hole, pterygium, corneal ulcer, post-trabeculectomy); does not directly test tobramycin. |
| NCT05313828 | N/A | Unknown | 40 | Compares treatment modalities for dendritic viral (HSV) corneal ulcer, not bacterial exposure keratitis. |
Both trials are of low direct relevance (Relevance Grade C) — neither tests tobramycin specifically in exposure keratitis, and both are listed with unknown recruitment status.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34987857 | 2021 | Case Report | Oxford Medical Case Reports | Multidrug-resistant Shewanella algae bacterial keratitis in a patient unable to voluntarily close his eyes — a direct clinical example of the exposure-keratitis risk pathway. |
| 12861116 | 2003 | Case Report | Eye & Contact Lens | Bilateral MRSA keratitis following photorefractive keratectomy (PRK). |
| 11581057 | 2001 | Case Report | Ophthalmology | First reported case of contact lens-associated Bacillus cereus keratitis linked to lens case contamination. |
| 2707046 | 1989 | In vitro study | Current Eye Research | Compared corneal epithelial cytotoxicity of aminoglycosides (including tobramycin) using a rabbit corneal cell culture model. |
| 17228760 | 2006 | Unclassified | Nippon Ganka Gakkai Zasshi | Compared minimum inhibitory concentration (MIC) and postantibiotic effect of antibiotic eye drops (Japan infectious keratitis surveillance). |
| 14574976 | 2003 | Unclassified | Yan Ke Xue Bao (Eye Science) | Case report of paracentral corneal dellen in Graves ophthalmopathy — indirect relevance only. |
| 33847093 | 2021 | Unclassified | Polish Journal of Veterinary Sciences | Feline ocular toxoplasmosis case series — veterinary, low direct relevance. |
Most publications are case reports or in vitro data rather than controlled clinical evidence, and only one (PMID 34987857) directly describes the exposure-keratitis clinical scenario.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for tobramycin in exposure keratitis is preclinical/mechanistic in nature (L4) — the two identified clinical trials are of low relevance (Grade C, unknown status, not testing tobramycin directly), and the literature is dominated by case reports and in vitro toxicity data rather than efficacy studies. The mechanistic rationale itself supports only an adjunctive anti-infective role rather than treatment of the underlying disorder, which does not currently justify progression beyond a research hypothesis.
To proceed, the following is needed:
- TFDA/EU safety labeling data (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed mechanism of action documentation via DrugBank (DG002)
- Direct clinical studies evaluating tobramycin prophylaxis/treatment specifically in exposure keratitis patients
- Clarification of feasible route of administration (topical ophthalmic) and dosing for this population
- Regulatory status confirmation, given the drug is currently listed as not marketed in the EU dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.